Premium
Comparison of 123 I‐metaiodobenzylguanidine (MIBG) and 131 I‐MIBG semi‐quantitative scores in predicting survival in patients with stage 4 neuroblastoma: A report from the Children's Oncology Group
Author(s) -
Naranjo Arlene,
Parisi Marguerite T.,
Shulkin Barry L.,
London Wendy B.,
Matthay Katherine K.,
Kreissman Susan G.,
Yanik Gregory A.
Publication year - 2011
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22991
Subject(s) - medicine , neuroblastoma , stage (stratigraphy) , cog , nuclear medicine , overall survival , oncology , log rank test , paleontology , genetics , artificial intelligence , computer science , biology , cell culture
Background 123 I‐metaiodobenzylguanidine (MIBG) scans are preferable to 131 I‐MIBG for neuroblastoma imaging as they deliver less patient radiation yet have greater sensitivity in disease detection. Both 123 I‐MIBG and 131 I‐MIBG scans were used for disease assessments of neuroblastoma patients enrolled on Children's Oncology Group (COG) high‐risk study A3973. The hypothesis was that 123 I‐MIBG and 131 I‐MIBG scans were sufficiently similar for clinical purposes in terms of ability to predict survival. Procedure Patients enrolled on COG A3973 with stage 4 disease who completed 123 I‐MIBG or 131 I‐MIBG scans at diagnosis, post‐induction, post‐transplant, or post‐biotherapy were analyzed. The performance of the Curie score for each MIBG scan type in predicting survival was evaluated. At each time point, survival curves for 123 I‐MIBG versus 131 I‐MIBG were compared using the log‐rank test. Results Of the 413 patients on A3973 with at least one MIBG scan, 350 were stage 4. The 5‐year event‐free survival (EFS) and overall survival (OS) rates were 33.4 ± 3.6% and 45.6 ± 4.0% (N = 350). At post‐induction, EFS ( P = 0.3501) and OS ( P = 0.5337) for 123 I‐MIBG versus 131 I‐MIBG were not significantly different. Similarly, comparisons at the three other time points were non‐significant. Conclusions We found no evidence of a statistically significant difference in outcome by type of scan. For future survival analyses of MIBG Curie scores, 123 I‐MIBG and 131 I‐MIBG results may be combined and analyzed overall, without adjustment for scan type. Pediatr Blood Cancer 2011;56:1041–1045. © 2011 Wiley‐Liss, Inc.